Keyur Pharmachem India Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 29-07-2024
- Paid Up Capital ₹ 0.10 M
as on 29-07-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.70 Cr
as on 29-07-2024
- Revenue -15.37%
(FY 2023)
- Profit -761.43%
(FY 2023)
- Ebitda -49.88%
(FY 2023)
- Net Worth -14.88%
(FY 2023)
- Total Assets -18.23%
(FY 2023)
About Keyur Pharmachem India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.70 Cr.
Chetan Rane and Suchita Rane serve as directors at the Company.
- CIN/LLPIN
U24233MH2011PTC220636
- Company No.
220636
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Aug 2011
- Date of AGM
18 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Keyur Pharmachem India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chetan Rane  | Director | 08-Aug-2011 | Current |
| Suchita Rane | Director | 08-Aug-2011 | Current |
Financial Performance of Keyur Pharmachem India.
Keyur Pharmachem India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 15.37% decrease. The company also saw a substantial fall in profitability, with a 761.43% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Keyur Pharmachem India?
In 2023, Keyur Pharmachem India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 28 Feb 2024 | ₹6.70 M | Open |
Indian Bank Creation Date: 17 Aug 2020 | ₹1.34 M | Open |
Indian Bank Creation Date: 12 Dec 2018 | ₹7.50 M | Open |
How Many Employees Work at Keyur Pharmachem India?
Keyur Pharmachem India has a workforce of 16 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Keyur Pharmachem India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Keyur Pharmachem India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
